Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Immunotherapy, Adoptive"" wg kryterium: Temat


Tytuł :
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Autorzy :
Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: .
Tam CS; Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia.
Borchmann P; Clinic I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Worel N; Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
McGuirk JP; Department of Internal Medicine, The University of Kansas Health System, Kansas City, KS, USA.
Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Waller EK; Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, USA.
Jaglowski S; Blood and Marrow Transplant Program, James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Bishop MR; Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Damon LE; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Foley SR; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Westin JR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Fleury I; Department of Lymphoma and Myeloma, Maisonneuve-Rosement Hospital, University of Montreal, Montreal, QC, Canada.
Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia.
Mielke S; Department of Medicine II, University of Würzburg Medical Center, Würzburg, Germany; Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Teshima T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Janakiram M; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA.
Hsu JM; Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kersten MJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Ghosh M; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Wagner-Johnston N; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Kato K; Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Corradini P; Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
Martinez-Prieto M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Han X; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Tiwari R; Novartis Healthcare, Hyderabad, India.
Salles G; Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France.
Maziarz RT; Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1403-1415. Date of Electronic Publication: 2021 Sep 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/mortality
Lymphoma, Large B-Cell, Diffuse/*therapy
Receptors, Antigen, T-Cell/*therapeutic use
T-Lymphocytes/*transplantation
Australia ; Europe ; Female ; Humans ; Japan ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; North America ; Progression-Free Survival ; Recurrence ; T-Lymphocytes/immunology ; Time Factors
Czasopismo naukowe
Tytuł :
Regulatory hurdles for CAR T-cell therapy in Japan.
Autorzy :
Nagai S; Department of Medical Development, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Oct; Vol. 8 (10), pp. e686-e687.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy, Adoptive*/economics
Immunotherapy, Adoptive*/legislation & jurisprudence
Immunotherapy, Adoptive*/methods
Clinical Trials as Topic ; Humans ; Japan/epidemiology ; Lymphoma, B-Cell/epidemiology ; Lymphoma, B-Cell/therapy ; Marketing ; Receptors, Chimeric Antigen/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
Autorzy :
Hefazi M; Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Bolivar-Wagers S; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Blazar BR; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Sep 07; Vol. 22 (18). Date of Electronic Publication: 2021 Sep 07.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Graft vs Host Disease/*therapy
T-Lymphocytes, Regulatory/*immunology
T-Lymphocytes, Regulatory/*metabolism
Animals ; Biomarkers ; Cytokines/metabolism ; Energy Metabolism ; Genetic Engineering ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Immunomodulation ; Immunophenotyping ; Translational Medical Research
Czasopismo naukowe
Tytuł :
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.
Autorzy :
Dimou M; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; .
Bitsani A; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Bethge W; Department Hematology & Oncology Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany.
Panayiotidis P; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Vassilakopoulos TP; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2021 Nov-Dec; Vol. 35 (6), pp. 3401-3406.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*
Neoplasm Recurrence, Local*
Antibodies, Monoclonal, Humanized/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Antigens, CD19 ; Biological Products ; Humans ; Remission Induction
Czasopismo naukowe
Tytuł :
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Autorzy :
Shi J; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Zhang Z; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Cen H; Guangxi Medical University Cancer Hospital, Guangxi, 530021, China.
Wu H; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Zhang S; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Liu J; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Leng Y; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Ren A; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Liu X; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Zhang Z; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Tong X; Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Liang J; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China.
Li Z; Guangxi Medical University Cancer Hospital, Guangxi, 530021, China.
Zhou F; Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Huang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wuhan, 430030, China.
Qin Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yang K; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang T; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China. .; Key Lab of Industrial Fermentation Microbiology of the Ministry of Education and Tianjin Key Lab of Industrial Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China. .
Zhu H; Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, 430081, China. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Oct 09; Vol. 14 (1), pp. 162. Date of Electronic Publication: 2021 Oct 09.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
12E7 Antigen/*immunology
Immunotherapy, Adoptive/*methods
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Receptors, Chimeric Antigen/*therapeutic use
12E7 Antigen/antagonists & inhibitors ; Animals ; Blood Cells/drug effects ; Cell Line, Tumor ; Humans ; Immunotherapy, Adoptive/adverse effects ; Mice ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Receptors, Chimeric Antigen/immunology
Raport
Tytuł :
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Autorzy :
Mei H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. .; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China. .
Li C; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Jiang H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Zhao X; Institute of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, 434020, China.
Huang Z; Institute of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, 434020, China.
Jin D; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.; Zhejiang Cellyan Biotechnology Co. Ltd, Jiaxin, 314001, China.
Guo T; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Kou H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Liu L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Tang L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Yin P; Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Wang Z; Drug Clinical Trial Institution, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Ai L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Ke S; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Xia Y; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Deng J; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Chen L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Cai L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Sun C; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xia L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
Hua G; Zhejiang Cellyan Biotechnology Co. Ltd, Jiaxin, 314001, China.
Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. .; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Oct 09; Vol. 14 (1), pp. 161. Date of Electronic Publication: 2021 Oct 09.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
ADP-ribosyl Cyclase 1/*immunology
B-Cell Maturation Antigen/*immunology
Immunotherapy, Adoptive/*methods
Multiple Myeloma/*therapy
Receptors, Chimeric Antigen/*therapeutic use
ADP-ribosyl Cyclase 1/antagonists & inhibitors ; Adult ; Aged ; Animals ; B-Cell Maturation Antigen/antagonists & inhibitors ; Cell Line, Tumor ; Female ; Humans ; Immunotherapy, Adoptive/adverse effects ; Male ; Mice ; Middle Aged ; Molecular Docking Simulation ; Multiple Myeloma/immunology ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/therapy ; Receptors, Chimeric Antigen/immunology
Czasopismo naukowe
Tytuł :
Targeting BCMA in Multiple Myeloma.
Autorzy :
Tan CR; Myeloma Service Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, New York, NY, 10021, USA. .
Shah UA; Myeloma Service Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, New York, NY, 10021, USA.
Pokaż więcej
Źródło :
Current hematologic malignancy reports [Curr Hematol Malig Rep] 2021 Oct; Vol. 16 (5), pp. 367-383. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive*
Antineoplastic Agents, Immunological/*therapeutic use
B-Cell Maturation Antigen/*antagonists & inhibitors
Multiple Myeloma/*therapy
Animals ; Antibodies, Bispecific/therapeutic use ; B-Cell Maturation Antigen/metabolism ; Humans ; Immunoconjugates/therapeutic use ; Molecular Targeted Therapy
Czasopismo naukowe
Tytuł :
Optimization of lymphapheresis for manufacturing autologous CAR-T cells.
Autorzy :
Yamanaka I; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yamauchi T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Henzan T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Sakoda T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Miyamoto K; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Mishima H; Department of Medical Technology, Kyushu University Hospital, Fukuoka, 812-8582, Japan.
Ono H; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Koga Y; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Nakashima Y; Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Kato K; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Miyamoto T; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Mizuno S; Molecular and Cell Processing Center, Kyushu University Hospital, Fukuoka, 812-8582, Japan.
Ogawa Y; Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Ohga S; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Akashi K; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Maeda T; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Division of Precision Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Kunisaki Y; Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Oct; Vol. 114 (4), pp. 449-458. Date of Electronic Publication: 2021 Jul 17.
Typ publikacji :
Journal Article
MeSH Terms :
Batch Cell Culture Techniques*/methods
Immunotherapy, Adoptive*
Receptors, Chimeric Antigen/*immunology
Receptors, Chimeric Antigen/*metabolism
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Adolescent ; Adult ; Aged ; Biomarkers ; Child ; Child, Preschool ; Female ; Humans ; Immunophenotyping ; Infant ; Leukapheresis/methods ; Male ; Middle Aged ; T-Lymphocytes/cytology ; Young Adult
Czasopismo naukowe
Tytuł :
Optimized cytotoxicity assay for co-suspended effector and target cells.
Autorzy :
Cui L; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Yin F; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Cheng J; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Liu H; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Zheng M; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Liu D; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Wu Z; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China.
Qian Q; Shanghai Cell Therapy Group Co., LTD, Shanghai 201805, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of immunological methods [J Immunol Methods] 2021 Oct; Vol. 497, pp. 113100. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytotoxicity, Immunologic*
Immunohistochemistry*
Immunotherapy, Adoptive*
Killer Cells, Natural/*transplantation
Leukemia, Erythroblastic, Acute/*therapy
T-Lymphocytes, Cytotoxic/*transplantation
Antigens, CD19/genetics ; Antigens, CD19/immunology ; Cell Survival ; Coculture Techniques ; Epitopes ; Flow Cytometry ; Humans ; K562 Cells ; Killer Cells, Natural/immunology ; Leukemia, Erythroblastic, Acute/immunology ; Leukemia, Erythroblastic, Acute/pathology ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes, Cytotoxic/immunology
Czasopismo naukowe
Tytuł :
Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Autorzy :
Xie J; Analysis Group Inc., Los Angeles, CA, USA.
Wu A; Analysis Group Inc., Los Angeles, CA, USA.
Liao L; ADC Therapeutics Inc., New Providence, NJ, USA.
Nastoupil LJ; Department of Lymphoma-Myeloma, Division of Cancer Medicine, University of Texas, Houston, TX, USA.
Du EX; Analysis Group Inc., Los Angeles, CA, USA.
Noman A; Analysis Group Inc., New York, NY, USA.
Chen L; ADC Therapeutics Inc., New Providence, NJ, USA.
Pokaż więcej
Źródło :
Current medical research and opinion [Curr Med Res Opin] 2021 Oct; Vol. 37 (10), pp. 1789-1798. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Non-Hodgkin*/drug therapy
Receptors, Chimeric Antigen*
Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
Autorzy :
Mohyuddin GR; Division of Hematology and Hematological Malignancies, University of Utah, United States. Electronic address: .
Atieh T; Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas, United States.
Ahmed N; Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas, United States.
Sborov D; Division of Hematology and Hematological Malignancies, University of Utah, United States.
McClune B; Division of Hematology and Hematological Malignancies, University of Utah, United States.
Abdallah AO; Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas, United States.
Goodman AM; Division of Blood and Marrow Transplantation, University of California San Diego, United States.
Aziz M; Department of Gastroenterology, University of Toledo, United States.
Allen I; Division of Epidemiology and Biostatistics, University of California San Francisco, United States.
Prasad V; Divisions of Hematology & Medical Oncology, University of California San Francisco, United States.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Oct; Vol. 156, pp. 164-174. Date of Electronic Publication: 2021 Aug 26.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Antigens, CD19/*genetics
B-Cell Maturation Antigen/*genetics
Hematologic Neoplasms/*therapy
Receptors, Chimeric Antigen/*genetics
T-Lymphocytes/*transplantation
Clinical Trials as Topic ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/immunology ; Humans ; Intention to Treat Analysis ; Research Design ; T-Lymphocytes/immunology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Autorzy :
Martin T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Usmani SZ; Levine Cancer Institute-Atrium Health, Charlotte, NC, USA.
Schecter JM; Janssen R&D, Raritan, NJ, USA.
Vogel M; Janssen Global Services, LLC, Raritan, NJ, USA.
Jackson CC; Janssen R&D, Raritan, NJ, USA.
Deraedt W; Janssen R&D, Beerse, Belgium.
Tian H; Janssen R&D, Raritan, NJ, USA.
Yeh TM; Janssen R&D, Raritan, NJ, USA.
Banerjee A; Janssen R&D, Lower Gwynedd Township, PA, USA.
Pacaud L; Legend Biotech USA, Inc, Piscataway, NJ, USA.
Garrett A; Legend Biotech USA, Inc, Piscataway, NJ, USA.
Haltner A; EVERSANA, Sydney, NS, Canada.
Cameron C; EVERSANA, Sydney, NS, Canada.
Van Sanden S; Janssen R&D, Beerse, Belgium.
Diels J; Janssen R&D, Beerse, Belgium.
Valluri S; Janssen Global Services, LLC, Raritan, NJ, USA.
Samjoo IA; EVERSANA, Burlington, ON, Canada.
Pokaż więcej
Źródło :
Current medical research and opinion [Curr Med Res Opin] 2021 Oct; Vol. 37 (10), pp. 1779-1788. Date of Electronic Publication: 2021 Jul 23.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents*/therapeutic use
Immunotherapy, Adoptive*
Multiple Myeloma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Humans ; Progression-Free Survival ; Receptors, Chimeric Antigen
Czasopismo naukowe
Tytuł :
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Autorzy :
Leahy AB; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Newman H; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Li Y; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Liu H; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Myers R; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
DiNofia A; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Dolan JG; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Callahan C; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Baniewicz D; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Devine K; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Wray L; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Aplenc R; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
June CH; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; The Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Grupp SA; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Rheingold SR; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Maude SL; Division of Oncology and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Oct; Vol. 8 (10), pp. e711-e722.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Immunotherapy, Adoptive*
Antigens, CD19/*immunology
Central Nervous System Neoplasms/*therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Adult ; Central Nervous System Neoplasms/immunology ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Receptors, Chimeric Antigen/immunology ; Recurrence ; Young Adult
Czasopismo naukowe
Tytuł :
Localized Chemotherapy Based on Injectable Hydrogel Boosts the Antitumor Activity of Adoptively Transferred T Lymphocytes In Vivo.
Autorzy :
Cao Y; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.; Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, 3050 Kaixuan Road, Changchun, 130052, P. R. China.
Zhou Y; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.
Chen Z; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.
Zhang Z; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.
Chen X; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.
He C; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.
Pokaż więcej
Źródło :
Advanced healthcare materials [Adv Healthc Mater] 2021 Oct; Vol. 10 (19), pp. e2100814. Date of Electronic Publication: 2021 Jul 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hydrogels*
Immunotherapy, Adoptive*
T-Lymphocytes*
Neoplasms, Experimental/*therapy
Adoptive Transfer ; Animals ; Mice ; Mice, Inbred C57BL
Czasopismo naukowe
Tytuł :
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.
Autorzy :
Crombie JL; Dana-Farber Cancer Institute, Boston, MA.
Nastoupil LJ; University of Texas MD Anderson Cancer Center, Houston, TX.
Redd R; Dana-Farber Cancer Institute, Boston, MA.
Tang K; Baylor School of Medicine, Houston, TX.
Shouse G; City of Hope Cancer Center, Duarte, CA.
Herrera AF; City of Hope Cancer Center, Duarte, CA.
Chow VA; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Alliance, Seattle, WA; and.
Shadman M; University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Alliance, Seattle, WA; and.
Castaneda Puglianini O; Virginia Commonwealth University Medical Center, Richmond, VA.
Saucier A; Dana-Farber Cancer Institute, Boston, MA.
Jacobson CA; Dana-Farber Cancer Institute, Boston, MA.
Armand P; Dana-Farber Cancer Institute, Boston, MA.
Simmons G; Virginia Commonwealth University Medical Center, Richmond, VA.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Sep 28; Vol. 5 (18), pp. 3563-3567.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy, Adoptive*
Lymphoma, B-Cell*/drug therapy
Lymphoma, B-Cell*/epidemiology
Adult ; Antigens, CD19 ; Biological Products ; Humans
Czasopismo naukowe
Tytuł :
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Autorzy :
Wang G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.; Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Tianjin Medical University, Tianjin, 300070, China.
Sun X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Zuo S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Li C; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Niu Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Xia Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Meng Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Liu M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Fang Z; Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.
Yang X; Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, 200031, China.
Jiang Y; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China.
Wang S; Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430079, China.
Cui H; Department of Breast Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Huang H; Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
Zhou D; Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
Deng Q; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China. .
Pan J; State Key Laboratory of Experimental Hematology, Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China. .
Feng X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China. .; Key Laboratory of Immune Microenvironment and Disease of the Ministry of Education, Tianjin Medical University, Tianjin, 300070, China. .; Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Sep 16; Vol. 14 (1), pp. 149. Date of Electronic Publication: 2021 Sep 16.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*/methods
Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
Receptors, IgG/*genetics
Animals ; Cell Line, Tumor ; Gene Expression ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Mice
Raport
Tytuł :
Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy.
Autorzy :
Zhang M; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Zhao Z; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pritykin Y; Lewis-Sigler Institute for Integrative Genomics and Computer Science Department, Princeton University, Princeton, NJ 08540, USA.
Hannum M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Scott AC; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kuo F; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sanghvi V; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chan TA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Seshan V; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wendel HG; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Schietinger A; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sadelain M; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Huse M; Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2021 Sep 15; Vol. 13 (611), pp. eabg4328. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Epithelial Cell Adhesion Molecule*/genetics
Immunotherapy, Adoptive*
MicroRNAs*/genetics
Neoplasms, Experimental/*immunology
Animals ; Cell Line, Tumor ; Cell- and Tissue-Based Therapy ; Gene Expression Regulation, Neoplastic ; Mice, Inbred C57BL ; Mice, Transgenic ; T-Lymphocytes
Czasopismo naukowe
Tytuł :
[Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].
Autorzy :
Li YN; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Du MY; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Li CG; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Zhang YQ; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Luo WJ; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Kou HM; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Mei H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Pokaż więcej
Źródło :
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2021 Sep 14; Vol. 42 (9), pp. 739-746.
Typ publikacji :
Journal Article
MeSH Terms :
Hematologic Neoplasms*/complications
Hematologic Neoplasms*/therapy
Immunotherapy, Adoptive*
Infections/*etiology
Antigens, CD19 ; Cell- and Tissue-Based Therapy ; Humans ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Potential New Immune-Checkpoint Inhibitor Partner for Lung Cancer.
Autorzy :
Abbasi J
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Sep 14; Vol. 326 (10), pp. 901.
Typ publikacji :
Wiadomości
MeSH Terms :
Immunotherapy, Adoptive*
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*therapy
Nivolumab/*therapeutic use
Combined Modality Therapy ; Humans ; Interleukin-2/therapeutic use ; Lung Neoplasms/drug therapy ; Lymphocytes, Tumor-Infiltrating/transplantation
Periodyk

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies